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RAPPORT DE SYNTHESE 
La bronchopneumopathie chronique obstructive (BPCO) est l'indication la plus fréquente 
de la transplantation pulmonaire. Néanmoins, le bénéfice de survie dans cette indication 
est toujours débattu. Le but de cette étude était d'analyser l'impact de la transplantation 
pulmonaire sur la survie de patients BPCO à l'aide d'une nouvelle méthode utilisant l'index 
de BODE, un indice validé dans la prédiction de la survie de patients BPCO. L'index de 
BODE est composé de 4 variables (indice de masse corporelle, obstruction bronchique, 
dyspnée, capacité d'effort) et son score s'échelonne de 0 à 10, une valeur élevée 
signifiant une maladie plus sévère et donc une probabilité de survie moindre. 
Cette étude rétrospective a porté sur 54 patients BPCO ayant consécutivement bénéficié 
d'une transplantation pulmonaire (unilatérale ou bilatérale) au Centre Hospitalier 
Universitaire Vaudois et aux Hôpitaux Universitaires de Genève entre 1994 et 2007, avec 
un suivi jusqu'au 30 juin 2009. Le score de BODE avant transplantation a été calculé pour 
chaque patient, à partir duquel une survie prédite a été dérivée. Cette survie prédite a été 
comparée à la survie réelle des patients transplantés. 
Une majorité de patient (67%) a présenté un bénéfice individuel de survie suite à la 
transplantation pulmonaire. Ceci s'est vérifié aussi bien dans le sous-groupe de patients 
avec un score de BODE 2 7 que dans celui avec un score de BODE < 7. La survie 
médiane était significativement améliorée par la transplantation pulmonaire dans la 
cohorte totale et dans le sous-groupe avec un score de BODE 2 7, mais pas dans celui 
avec un score de BODE< 7. De plus, 4 ans après la transplantation, un bénéfice de survie 
ne peut être escompté que chez les patients présentant un score de BODE 2 7. 
Dans notre cohorte, la transplantation pulmonaire a donc conduit à un bénéfice individuel 
de survie chez la majorité des patients, quel que soit leur score de BODE avant 
l'intervention. Toutefois, un bénéfice global desurvie n'a pu être démontré que dans le 
groupe de patients ayant la maladie la plus sévère. Chez les patients moins sévèrement 
atteints, les risques liés à l'intervention sont plus importants que le bénéfice de survie 
escompté à long terme. Ces résultats confortent l'utilisation de l'index de BODE comme 
critère de sélection pour la transplantation pulmonaire chez les patients BPCO. 
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ABSTRACT: Chronic obstructive pulmonary disease (COPD) is the primary indication for lung 
transplantation (l Tx), but survival benefit is still under debate. We analysed the survival impact of 
L Tx in COPD with a new approach, using the BODE (body mass index, airway obstruction, 
dyspnoea, exercise capacity) index. 
We retrospectively reviewed 54 consecutive lung transplants performed for COPD. The pre-
transplant BODE score was calculated for each patient and a predicted survival was derived from 
the survival functions of the original BODE index validation cohort. Predicted and observed post-
transplant survival was then compared. 
ln the subgroups .with a BODE score "Ç-7 and <7, a majority of patients (66% and 69%, 
respectively) lived for longer after L Tx than predicted by their individual BODE index. The median 
survival was significantly improved in the entire cohort and in the subgroup with a BODE score "Ç- 7. 
4 yrs after L Tx a survival benefit was only apparent in patients with a pre-transplant BODE score 
of "Ç-7. 
ln conclusion, while a majority of COPD patients had an individual survival benefit from L Tx 
regardless of their pre-transplant BODE score, a global survival benefit was seen only in patients 
with more severe disease. This supports the use of the BODE index as a selection criteria for L Tx 
candidates. 
KEYWORDS: BODE index, chronic obstructive pulmonary disease, lung transplantation, patient 
selection, survival analysis 
hronic obstructive pulmonary disease 
(COPD) is a leading cause of morbidity 
and mortality around the world, making 
it one of the major challenges for the health-
care community. Medical treatfu.ent, including 
smoking cessation, bronchodilators, oxygen ad-
ministration, adequate diet and pulmonary reha-
bilitation, remains the primary management of 
COPD. However, these are often insufficient in 
patients with advanced disease. For selected 
patients, surgical options include bullectomy, 
ltmg volume reduction surgery and lung trans-
plantation (LTx) [1]. LTx for COPD was first 
reported in 1970, but has only been used on a 
larger scale since the late 1980s, coinciding with 
the improvement of the surgical technique and 
immunosuppressive therapy. COPD is presently 
the main indication for LTx, accounting for more 
than one third of the procedures [2]. 
Although lung transplantation for COPD 
improves lung function [3], exercise capacity [4] 
and quality of life [5], controversy remains 
regarding survival benefit. Studies conducted to 
date, whether showing a survival benefit [6-8] or 
not [9, 10], have compared the survival of 
patients who underwent transplantation with 
patients remaining on the waiting list. Despite 
having used different approaches to take into 
account differences between patients on waiting 
lists and those who underwent the procedure, 
bias cannot be excluded. 
In COPD patients, several univariate survival 
prognostic factors have been identified [11, 12]. 
However, the pathophysiology of COPD is 
complex and none of these factors alone is an 
accurate predictor of the survival of COPD 
patients. In 2004, from a large multicenter cohort 
of COPD patients CELu et al. [13] identified a 
combination of four variables which showed a 
strong association with survival in COPD: body-
mass index (B); airflow obstruction (O); dyspnoea 
(D); and exercise capacity (E). These variables 
were used to create the BODE index, a multi-
dimensional scoring system that was shown to be 
a better predictor of survival than the spirometric 
staging system developed by the American 
Thoracic Society [14]. The BODE index assigns a 
score from 0 to 10, with a higher score indicating 
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more severe disease and predicting a poorer outcome. Thus, 
the BODE index offers an opportunity to evaluate the natural 
history of COPD patients enrolled in a lung transplantation 
programme by using criteria that are free of the selection bias 
introduced by the decisions of the transplantation team. This 
was recently emphasised by the introduction of a BODE score 
~ 7 as a new recommended transplant criteria for COPD 
patients [15]. 
The primary goal of our study was to analyse the survival 
impact of lung transplantation in end-stage COPD patients, by 
comparing the effective post-transplant survival with the 
survival predicted by the BODE index as measured during 
pre-transplant clinical evaluation. The results were then 
applied to refine the selection criteria of LTx candidates. 
MATERIAL AND METHODS 
Study subjects 
We retrospectively reviewed all consecutive subjects who 
underwent single or bilateral LTx (SLT and BLT, respectively) 
for COPD at Lausanne and Geneva University Hospitals (both 
Switzerland), from the start of the programme in 1993 until the 
end of 2007, with a follow-up until June 30, 2009. The diagnosis 
of COPD had been verified by a global assessment in every 
patient before listing, i.e. before the patient has an active status 
on the waiting list, with simultaneous assessment of suitability 
for L Tx and potential cardiovascular, infectiôus or psychiatrie 
contraindications to the procedure. Subjects with COPD 
related to a1-antitrypsin deficiency were excluded from the 
study. 
Data collection 
Demographic and clinical characteristics collected during the 
pre-transplant assessment period were recorded from the 
patient's chart, as well as the time to LTx and the type of 
procedure. The date of death, when applicable, was collected 
through centre-specific databases. 
BODE index calculation 
The pre-transplant BODE index score was calculated for each 
patient as described by CELLI et al. [13], using data obtained 
during the pre-transplant assessment: body mass index 
(kg·m-2); post-bronchodilator forced expiratory volum~ in 1 s 
(FEV1) as percentage of the predicted value; score on the 
modified Medical Research Council (MMRC) dyspnoea scale; 
and 6-min walking distance (6MWD). Spirometry measure-
ments and equations used to determine the predicted normal 
values for FEVl were in accordance with the official statement 
of the European Respiratory Society for Standardized Lung 
Function Testing [16]. MMRC was collected or retrospectively 
evaluated from the patient's chart when necessary. 6-min walk 
tests without encouragement were performed. Missing 6MWD 
(n=3) were derived from the maximum oxygen uptake 
(V'o2,max) measured during the pre-transplant assessment 
using the equations developed by CAHALIN et al. [17] in 
transplant candidates with end-stage lung disease. A 0 m 
6MWD was assigned to the two patients who were not able to 
perform the 6-min walk test or the V'o2,max test because of 
their respiratory condition. 
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Data analysis 
W e used the baseline survival function derived from the 
original BODE index cohort and provided by CELLI et al. [13]. 
The 95% confidence interval (Cl) of the hazard ratio was used 
to calculate the lower boundary, intermediate and upper 
boundary of life expectancy for each BODE level. The 
predicted survival with lower and upper estimates of each 
patient was then individually calculated as derived from their 
BODE score, and compared to their effective post-transplant 
survival. Patients who were still alive at the end of the follow-
up but had not yet achieved the upper boundary of their 
predicted survival were excluded from the analysis as the 
survival impact of L Tx could not be evaluated. The survival 
effect of the procedure on the entire cohort was then assessed 
by comparing the predicted survival with the effective 
survival, and by determining the number of patients who 
individually benefited from the procedure. The same analysis 
was repeated in the subgroups with a pre-transplant BODE 
score <7 and ~7. The survival after SLT versus BLT, and the 
difference between transplant periods were also analysed. 
Statistica/ analysis 
A paired t-test and Chi-squared test were used when 
appropriate to compare patient's characteristics. The survival 
effect of LTx on the entire cohort and on BODE score 
subgroups were assessed by a Wilcoxon signed ranks test. 
Kaplan-Meier survival estimates were used to describe the 
post-transplant survival of the entire cohort and log rank test 
was used to compare the survival between types and periods 
of transplant, and between pre-transplant BODE subgroups. 
Statistical analyses were performed with SPSS 17.0 for 
Windows (SPSS Inc. Chicago, IL, USA). 
RESULTS 
A total of 54 patients with COPD unrelated to cti-antitrypsin 
deficiency underwent LTx from Jtme 1993 until the end of 
2007. No COPD patients listed for transplantation died during 
the waiting period. 26 (48%) procedures were performed at 
Geneva University Hospitals and 28 (52%) in Lausanne, using 
a similar surgical and medical approach. 35 (65%) patients 
underwent BLT whereas 19 (35%) tmderwent SLT. At the end 
of the follow-up, 29 (54%) patients were still alive. Six of these 
patients had not yet achieved the upper boundary of their 
predicted survival according to their pre-transplant BODE 
index and were excluded from survival analysis. The flow 
chart of the patients and life stah1s at the end of the follow-up 
is shown in figure 1. 
The cohort included a patient with a low BODE score of 2, 
where the estimated half-life could not be calculated according 
to the data from the BODE original survival function [13]. 
Instead, the half-life was conservatively estimated according to 
the survival curve of the cohort of COPD patients described by 
MARTINEZ et al. [18]. One patient was re-transplanted during 
the study period and his survival time was calculated from the 
first LTx to death. Baseline characteristics of the transplanted 
patients are shown in table 1. Excluded patients did not differ 
significantly from the cohort used for survival analysis with ~ 
respect to baseline characteristics. The mean±SD follow-up 
was 5.7 ±4.5 yrs. 
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Patients with LTx for COPD (n=54) 
Status al the end of follow-up: 
Alive, n=29 
Deceased, n=25 
... 1 Excluded patients due to 1 
~ 1 insufficient follow-up (n=6) 
~, 
Patients used for survival analysis (n=48) 
Status at the end of follow-up: 
Alive, n=23 
Deceased, n=25 
FIGURE 1. Flow-chart of the patients and lite status at the end of the follow-up. 
l Tx: lung transplantation; COPD: chronic obstructive pulmonary disease. 
The comparison between observed post-transplant survival 
and expected survival according to pre-transplant BODE index 
is shown in table 2. For the whole cohort, the median survival 
was significantly improved after L Tx. This survival benefit was 
seen in the subgroup with a BODE score );7, but not in the 
subgroup with a BODE score <7, although a trend toward 
better survival with L Tx was present. An individual survival 
benefit was seen in two thirds of the L Tx recipients, regardless 
of their BODE score subgroup. The detailed survival loss or 
gain for each patient is shown in figure 2. It appears that a 
majority of patients lived much longer than expected while 
others, mainly in the BODE score <7 subgroup, experienced a 
potential survival loss. 
A sensitivity analysis on the effect of the exclusion of six 
patients from the survival analysis was performed. A 
pessimistic, intermediate or optimistic survival was assigned 
to each of these excluded patients using the quartile 1, median 
and quartile 3, respectively, of the survival observed in the 
other patients who reached at least the same post-transplant 
survival. These six patients were then included in the analysis. 
In the entire cohort (n=54), the median post-transplant 
survival (pessimistic: 5.4 yrs; intermediate: 6.3 yrs; optimistic: 
6.3 yrs) was significantly higher than the expected survival 
(lower boundary: 2.8 yrs; intermediate: 3.5 yrs; upper bound-
ary: 4.2 yrs) in all cases. In the BODE );7 subgroup (n=35+2), 
the significant survival benefit of LTx was strengthened when 
compared to the lower boundary and intermediate expected 
survivais, and there was a trend towards benefit when 
compared to the upper boundary of predicted survival. The 
BODE<7 subgroup (n=13+4) had a significant survival benefit 
from L Tx only when compared to the lower boundary of the 
expected survival. 
We found no significant survival difference between SLT and 
BLT subgroups, which had no between group pre-transplant 
differences. The period of transplant (1993-1999 versus 2000-
2007) was not associated with a survival difference. 
The Kaplan-Meier post-transplant survival was not different 
between pre-transplant BODE score subgroups (fig. 3). This 
allowed us to compare the predicted survival at each step of 
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the BODE index with the effective Kaplan-Meier post-
transplant survival of the entire cohort (table 3). This theore-
tical analysis showed that 4 yrs after L Tx the survival benefit is 
limited to patients with a pre-transplant BODE score ); 7. 
DISCUSSION 
This study showed a significant survival benefit of LTx in our 
cohort of COPD patients, with a median survival time 
significantly higher than expected prior to transplant. 
Considering that almost half of the patients were still alive at 
the end of the follow-up (fig. 1) these results are particularly 
relevant, as the importance of the survival benefit may have 
been underestimated due to a limited follow-up period. 
Moreover, a majority of patients had an individual benefit 
from the intervention in terms of survival. 
These results support two previous studies that have shown a 
global survival benefit after 260 days [6] and 369 days [7], as 
well as a recent complex statistical simulation on the United 
Network for Organ Sharing database which showed a survival 
benefit in a majority of transplanted patients [8]. Two other 
studies did not demonstrate a survival benefit after 48 months 
[9] and 24 months [10] of follow-up, but the follow-up time of 
the latter was too short to allow meaningful comparisons. 
Methodologically, we used the pre-transplant BODE index to 
predict a theoretical survival at time of LTx. In contrast, the 
five studies published to date compared, either directly or with 
a statistical model, the survival of transplanted patients with 
lung recipient candidates who remain on the waiting list. 
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Survival Joss Survival gain 
BODE ?.7 •• 0 0 OO 
BODE<? 
<> <> 
-8 -6 -4 -2 0 2 4 6 8 10 12 
Time yrs 
FIGURE 2. lndividual survival impact of lung transplantation of each patient. 
lndividual survival loss or gain was obtained for each patient by comparing the 
observed post-transplant survival with the 95% confidence interval upper boundary 
of predicted survival according to pre-transplant BODE score (body mass index, 
airway obstruction, dyspnoea, exercise capacity) .. Patients are separated into two 
subgroups based on their pre-transplant BODE score: BODE )' 7 {n=35; •, 0) 
and BODE <7 (n=13; +, <>). Patients still alive at the end of the follow-up {<>, O} 
are presented differently to highlight thelr potentially longer survival gain. +, lit: 
deceased at the end of follow-up. 
This method of comparing survival is susceptible to potential 
bias agaînst L Tx. Indeed, the initial assumption is that ail 
patients on the waitîng list need a lung transplant at the time of 
listing. However, considerîng the usual duration of the waitîng 
time (often beyond 2 yrs) [6, 19), transplant centres may register 
their patients early [20), which would improve the survival rate 
of the waitîng list population. Furthermore, if patients on 
the waiting list are good candidates for transplantation at the 
time of listing, progressÙm of the disease and ageîng durîng 
waitîng time makes them potentially worse candidates as 
older recipients have a significantly worse survival rate [2]. 
1.0 - , 
LI 
0.8 
ro 
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0.2 
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0 2 4 6 8 10 12 14 16 
Time post-lung transplantation yrs 
FIGURE 3. Observed post-transplant survival: di1ference between pre-trans-
plant BODE (body mass index, airway obstruction, dyspnoea, exercise capacity) ~ 
score subgroups. --: BODE <7, n=13; ........ :BODE =7, n=16; - - - - -: BODE 
>7, n=19. p=0.62. 
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In contrast, high-risk patients have an increased probability of 
dying while on the waiting list compared with low-risk patients 
who can survive long enough to undergo L Tx. This could bias 
the results in favour of LTx. The different type of care received 
by patients on the waiting list compared to those not considered 
or denied for L Tx is another probable major potential bias. By 
assigning a BODE score-based predicted survival time, post-
LTx survival can be compared with the predic.ted "natural" 
survival of the same patients, thus avoiding such risk of bias. 
The post-LTx survival rates of our cohort, 77% at 1 yr, 71% at 
2 yrs and 65% at 4 yrs, are in accordance with previous studies 
in COPD patients [2, 21-23]. The short waiting time 
(6±4 months) and the absence of death while on the waiting 
list in our cohort may differ from other transplantation centres. 
However, our centres apply standard surgical and medical 
procedures, and the model used in this study is independent of 
any waiting list consideration. Therefore, our findings are 
applicable to other L Tx centres. 
Survival benefit is not the sole criteria to consider when 
evaluating the benefit of L Tx in COPD patients, as L Tx leads to 
a dramatic improvement in quality of life [5]. However, owing 
to the chronic shortage of lung donors, it is well accepted that 
L Tx for COPD patients should be limited to a subset of those 
having the worst survival probability without intervention. 
The presence of an FEVl <25% pred, an arterial carbon dioxide 
tension ):55 mmHg (7.3 kPa) or pulmonary arterial hyperten-
sion with progressive deterioration has been used for many 
years as the standard guidelines for the selection of COPD lung 
transplant candidates [24]. NATHAN et al. [25] were the first to 
recommend the additional use of the BODE index, and 
proposed a BODE score )': 7 as a new transplant criteria. In 
2006, the International Society of Heart and Lung 
Transplantation formalised the use of the BODE score in the 
guidelines for the selection of lung transplant candid.ates [15], 
by adding a BODE index score )': 7 for transplantation and ):5 
for referral. 
We found that the post-transplant mortality risk did not 
depend on the pre-operative BODE index. Based on the 
observed survival in our cohort, the theoretical comparison 
with the survival predicted by each score of the BODE index 
showed a significant benefit at 4 yrs only with a pre-transplant 
BODE score ):7. Moreover, in our cohort, we found that LTx 
improved the median survival only in the subgroup with a 
BODE score ):7. In the subgroup with a BODE score <7, the 
mortality related to the intervention is higher than the long-
term expected benefit. Thus, these patients should not be 
transplanted at this stage of the disease or the indication 
should at least be carefully re-examined. Our results highlight 
the need for the BODE index to become part of ail pre-
transplant assessments in COPD patients and provide support 
to the official recommendation to use a eut-off BODE score of 7 
as· transplant criteria. 
Our cohort's baseline BODE scores distribution was signifi-
cantly higher than in the original BODE index validation 
cohort [13] (fig 4), reflecting the severity of COPD. The BODE 
index has not been specifically validated in a population listed 
for transplantation such as our cohort, but several factors 
suggest that this does not contraindicate its use. Not only did 
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al! our patients meet the inclusion criteria of CELLI et al. [13), 
but almost 50% of the BODE index validation cohort had 
BODE scores ;;.5 and, therefore, could have been referred for 
LTx as presently recommended [15]. More importantly, the 
BODE index has already proven its ability to predict mortality 
in severe COPD patients included in the National Emphysema 
Treatment Trial study [18). These patients were probably 
selected and followed as closely as patients listed for LTx. 
Moreover, the use of 95% CI of the survival predicted by the 
BODE index probably accounts for most of the differences 
between patients which are not evaluated by the BODE index, 
such as age, presence of pulmonary hypertension or other 
comorbidities. Nevertheless, the possibility that, due to a 
positive selection bias, the BODE index might be less accurate 
at predicting mortality in a cohort listed for transplantation has 
to be considered when interpreting the results of our study. 
The determination of BODE index scores from data collected 
during pre-transplant assessment is another limitation that 
should be recognised. Consequently, the calculated theoretical 
survival was not identical to the one at the time of L Tx. 
However, considering the short waiting time (6±4 months), a 
significant worsening of patients conditions during this time is 
unlikely. The absence of deaths during this period reinforces 
this hypothesis. In any case, it would result in an under-
estimation of BODE index scores at the time of transplant and, 
thus, an overestimation of the predicted survival time. 
Consequently, we would have found a higher survival benefit 
of LTx. 
In summary, the results of this study showed a significant 
survival benefit of LTx in our cohort of COPD patients. 
Importantly, not only was the median survival improved with 
L Tx but a significant majority of patients had an individual 
survival benefit from this procedure. Although the latter was 
independent from pre-transplant BODE score, the former was 
seen in the entire cohort and in the subgroup with a BODE 
score ;;:. 7, but not in the subset of patients with a BODE score 
<7. Moreover, in a theoretical analysis, we found that 4 yrs 
after L Tx a survival benefit could only be expected in the 
patients with a pre-transplant BODE score ;;:. 7. For those with 
35 
30 
25 
'$. 20 
t:: 
0 
.c 
0 15 ü 
10 
5 
0 
0 2 3 4 5 6 7 8 9 10 
BODE index score 
FIGURE 4. BODE (body mass index, airway obstruction, dyspnoea, exercise 
capacity) index repartition: studied transplanted cohort (Ill) versus original BODE 
index validation cohort (F'i). Data modified from [13]. 
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low BODE scores, the risk of the procedure outweighs the 
survival benefit. These results support the current recommen-
dation to use a BODE score ;;:. 7 as transplant criteria for 
patients with COPD. 
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